Abstract
Molecular testing sensitivity, which allows for early diagnosis of the 2019 coronavirus disease (COVID-19), could be affected by sample quality, storage, and transportation timeframe to the laboratory, along with bias related to the pre-analytic phase. The present study reports the selection and decontamination of nasopharyngeal samples during COVID-19 management at the Institut Pasteur Côte d'Ivoire. The objective of this work was to organize sample reception management and report a complete picture of sample selection and decontamination in the context of diagnosis activity decentralization. An administrative note creating the selection and decontamination unit of nasopharyngeal samples initiated activities in May 2020. The required human resources and necessary materials were identified and put in place. Daily activity consisted of receiving, sorting, decontaminating, and sending nasopharyngeal samples to different diagnostic laboratories. Nonconformities were recorded monthly. After a six-month period of activities, from a total amount of 11,401 containers received and decontaminated, 174,085 samples were selected. A proportion of 92.0% of these specimens met the diagnostic standards, while 7.0% that were found acceptable showed minor irregularities. Nevertheless, a rate of 1.0% of samples with major abnormalities could not be used for COVID-19 testing and, therefore, were rejected. Additionally, the non-conformity rate was reduced by 2.4% after the first term activity. Sorting and decontamination of nasopharyngeal samples are crucial steps in biosafety optimization for the technical staff and quality improvement of sample care.